Pfizer and China Resources Pharmaceutical Commercial signed a cooperation agreement in the fields of breast cancer and lung cancer drugs
On November 26th, Pfizer Investment Co., Ltd. and China Resources Pharmaceutical Commercial Group Co., Ltd. officially signed a strategic cooperation agreement. Both parties will jointly promote the commercialization of four high-quality mature drugs for lung cancer and breast cancer—Anew® (阿诺新®), Abraxane® (爱博新®), Famera® (法玛新®), and Secru® (赛可瑞®), expanding patient accessibility
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments